Majority of High-Containment CMO Facilities Located in 5EU and Switzerland, Notes GlobalData

Article

The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.

The latest research from GlobalData has revealed that more than two-thirds (69%) of contract manufacturing organizations (CMOs) high-containment facilities are based in the top five European Union countries (5EU-France, Germany, Italy, Spain, and the United Kingdom) and Switzerland.

“As is to be expected, the 5EU, as well as Switzerland, house the most small-molecule API facilities with containment in Europe,” said Adam Bradbury, PharmSource analyst at GlobalData, in an Aug. 8, 2019 press release. “Most of these belong to dedicated CMOs [contract manufacturing organizations], which only perform contract manufacturing rather than also marketing their own products.”

Manufacturing requirements for highly potent drug substances is becoming more routine as a result of the rising proportion of biologics and complex entering the drug development pipeline. These complex ingredients are useful in fields such as oncology; however, their appropriate handling requires very special equipment, facilities, and skill levels.

“The manufacture of chemical APIs has become lucrative due to its growing complexity, using materials that are poorly soluble or require containment, which makes their handling more difficult,” continued Bradbury. “Approximately half of oncology drug candidates in Phase III and pre-registration are small molecules. This highlights that small-molecule cytotoxic oncology will play a major role in upcoming approvals and is good news for small-molecule CMOs as small-molecule drugs tend to be outsourced more than biologics.”

Source: GlobalData

 

Recent Videos
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content